Document is current

Article History

Received: 22 October 2024

Accepted: 10 December 2024

First Online: 19 February 2025

Declarations

:

: Jérôme de Sèze: consultant, advisory boards, and scientific meetings for Alexion, Biogen, CSL Behring, Genzyme/Sanofi, Horizon Therapeutics, LFB, Janssen, Novartis, Roche, and Teva. Pierre Labauge: congresses and research grants from Biogen, BMS, Merck, Novartis, Sanofi Genzyme, and Teva. Roland Liblau: research grants from BMS, GSK, and Roche; speaker fees from Biogen, Merck, Novartis, Roche, and Sanofi Genzyme. Mikel Martinez: no conflicts of interest to disclose. Thibault Moreau: research support and consultancy fees from Biogen, Merck, Novartis, Roche, and Sanofi. Laurent Suchet: consulting fees from Biogen, BMS-Celgene, Merck, Novartis, Roche, and Sanofi Genzyme; honoraria from Novartis and Sanofi. Patrick Vermersch: honoraria from AB Science, Ad Scientiam, Biogen, BMS-Celgene, Imcyse, Janssen, Merck, Novartis, Roche, Sanofi Genzyme, and Teva; research support from Novartis, Roche, and Sanofi Genzyme. Sandra Vukusic: lecturing fees, travel grants, and research support from Biogen, BMS-Celgene, Janssen, Merck, Novartis, Roche, Sandoz, and Sanofi Genzyme. Guillaume Mathey: no conflicts of interest to disclose. Laure Michel: no conflicts of interest to disclose. Jonathan Ciron: consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, Biogen, Horizon Therapeutics, Novartis, Merck, Roche, and Sanofi Genzyme. Aurelie Ruet: received honoraria for meeting speaking from Alexion, Horizon Therapeutics, Merck, and Sanofi Genzyme; received support for traveling from Biogen, Merck, and Novartis. Her institution received research grants from Biogen, BMS, Roche, and Sanofi Genzyme. Elisabeth Maillart: consulting and lecturing fees from Alexion, Biogen, Horizon, Janssen, Merck Serono, Novartis, Roche, Sandoz, Sanofi Genzyme, and Teva Pharmaceuticals; and research support from Biogen. Helene Zephir: consulting or lectures, and invitations for national and international congresses, from Bayer, Biogen, Merck, Novartis, Sanofi Genzyme, and Teva; research support from Roche and Teva; and academic research grants from Académie de Médecine, ARSEP Foundation, FHU Imminent, and LFSEP. Caroline Papeix: no conflicts of interest to disclose. Gilles Defer: consulting and lecturing fees for Biogen, Genzyme, Merck Serono, Novartis, Roche, and Teva; and funding for travel from Biogen, Merck Serono, Novartis, Sanofi Genzyme, and Teva. Institution granted for research supporting from Biogen, Genzyme, Merck Serono, and Novartis. Mikael Cohen: has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ad Scientiam, Alexion, Biogen, Celgene-BMS, Horizon Therapeutics, Janssen, Merck, Roche, and Sanofi. David Axel Laplaud: served on scientific advisory boards for Alexion, Biogen, BMS, Janssen, Merck, Novartis, Roche, and Sanofi; received conference travel support and/or speaker honoraria from Alexion, Biogen, BMS, Merck, Novartis, Roche, and Sanofi; and received research support from Agence Nationale de la Recherche, Fondation ARSEP, and Fondation EDMUS.​ Eric Berger: honoraria and consulting fees from Biogen, Genzyme, Novartis, Roche, Sanofi Aventis, and Teva Pharma. Pierre Clavelou: consulting and lecturing fees, travel grants, and unconditional research support from Biogen, Janssen, Medday, Merck, Novartis, Roche, Sanofi Genzyme, and Teva Pharma. Eric Thouvenot: consulting and lecturing fees, travel grants, or unconditional research support from Actelion, Biogen, Janssen, Merck Serono, Novartis, Roche, and Sanofi. Olivier Heinzlef: consulting and lecturing fees from Almirall, Bayer Schering, Biogen Idec, Genzyme, Merck, Novartis, and Teva; travel grants from Biogen Idec, Genzyme, Merck Serono, Novartis, and Teva; and research support from Roche, Merck, and Novartis. Jean Pelletier: no conflicts of interest to disclose. Claire Giannesini: no conflicts of interest to disclose. Olivier Casez: Biogen (personal fees), Janssen (personal fees), Merck (personal fees, non-financial support [traveling/congress]), Novartis (personal fees, non-financial support [traveling/congress]), Roche (personal fees, non-financial support [traveling/congress]), and Sanofi (personal fees). Bertrand Bourre: served on scientific advisory board for Alexion, Biogen, BMS, Horizon, Janssen, Merck, Novartis, Roche, Sandoz, and Sanofi; and received funding for travel and honoraria from Alexion, Janssen, Merck, Novartis, Roche, and Sanofi. Abir Wahab: provided expert testimony for Roche and received travel grants from Biogen. Laurent Magy: no conflicts of interest to disclose. Jean-Philippe Camdessanché: consulting and lecturing fees from Akcea, Alexion, Alnylam, Argenx, Biogen, Bristol Myers Squibb, CSL Behring, Genzyme, Grifols, Laboratoire Français des Biotechnologies, Merck Serono, Natus, Novartis, Pfizer, Pharmalliance, SNF-Floerger, Teva, and UCB Pharma; travel grants from Akcea, Alexion, Alnylam, Argenx, Biogen, CSL Behring, Genzyme, Grifols, Laboratoire Français des Biotechnologies, Merck Serono, Natus, Novartis, Pfizer, SNF-Floerger, and Teva. Inès Doghri: no conflicts of interest to disclose. Céline Labeyrie: no conflicts of interest to disclose. Karolina Hankiewicz: no conflicts of interest to disclose. Jean-Philippe Neau: no conflicts of interest to disclose. Corinne Pottier: support from Alexion, Biogen, Merck, Novartis, Roche, and Teva. Pamela Dobay, Seth Levin, Marilyn Gros, Marta Ruiz: employees of Biogen and may own stock in the company. Hanyue Li: employee of Biogen and may have owned stock in the company at the time this work was conducted. Fabien Rollot: no conflicts of interest to disclose.

: In accordance with French legislation, the OFSEP cohort was approved by the national data protection agency (Commission Nationale de l’Informatique et des Libertés; authorization request 914066v3) and the French ethical committee (Comité de Protection des Personnes: reference 2019-A03066-51). All patients in the OFSEP cohort provided informed consent to have their medical data shared anonymously for research purposes. Appropriate research information on the OFSEP registry research cohort is available on the OFSEP website [, ]. After 1 month without objections from the patient, patient data were extracted for analysis. As per French legislation (“Loi Informatique et Libertés” No. 78–17 on January 6, 1978, modified by Law No. 2016–41 on January 26, 2016), LymphoTEC was registered on ClinicalTrials.gov (NCT04756687) and was compliant with the “French Methodology of reference MR-004”. The study was conducted in accordance with the Declaration of Helsinki.